Navigation Links
Frost & Sullivan: Novel Diagnostics Methods Driving the European Cancer IVD Market Towards Early Detection and Prevention
Date:2/24/2009

LONDON, Feb. 24 /PRNewswire/ -- Early detection is the key focus of cancer diagnostics. Traditional testing methods such as immunoassay testing are facing fierce competition from evolving segments such as nucleic acid amplification technology (NAT) and immunohistochemistry testing. The ability to prove the clinical utility and practical use of the test within a laboratory is one of the essential requirements to be successful in this market.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan (http://www.drugdiscovery.frost.com), European Cancer IVD Market, finds that the market earned revenues of $623.5 million in 2008 and estimates this to reach $1.5 billion in 2015.

"Intense research for the development of new cancer therapies is increasing the demand for tests to guide physicians in the selection of appropriate treatments," notes Frost & Sullivan Research Analyst Gayathry Ramachandran. "Repeated test requests, especially for prostrate specific antigen (PSA) will boost market revenues."

The increased prevalence of cancer has resulted in the development of novel technologies that support the effective diagnosis of cancer. Rising awareness, paralleled by the mounting use of cancer screening tests will promote the growth of the European cancer IVD market over the long term.

The importance of molecular tests has been elucidated by the success of the human genome project. This has allowed the rapid proliferation of specific nucleic acid tests for the detection of tumour markers and this trend holds strong potential for the growth of the market.

"The human genome project has encouraged the cancer genome project, where high throughput techniques are developed to detect the mutated genes responsible for cancer," explains Ramachandran. "Sizeable funding for cancer disease research programmes is also fuelling the development of cancer diagnostic tests."

However, most cancer markers are not indicative of the progression of the disease or its incidence. Inspite of tremendous strides in knowledge, the details of the biochemical and bio-cellular nature of cancer are still poorly understood.

"The validation of new tests is mandatory and challenges market participants to obtain certain regulatory approvals," cautions Ramachandran. "Validation is a problem in multiplexing assays because the establishment of equivalency is difficult."

The future of the cancer IVD market lies in the efforts and initiatives taken by governments to encourage R&D into companion diagnostics and predictive assays. This will determine the future of the market.

At the same time, alliances with pharmaceutical companies will mutually benefit both diagnostics and pharmaceutical companies, while accelerating the development of innovative tests and targeted drugs.

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the European cancer in vitro diagnostic (IVD) market, then send an e-mail to Katja Feick, Corporate Communications, at katja.feick@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by e-mail.

European Cancer IVD Market is part of the Drug Discovery & Clinical Diagnostics Growth Partnership Services programme, which also includes research in the following markets: European Immunodiagnostics Market, European POC Connectivity Market, European Immunoassay Diagnostics Market, Western European IVD Markets, and Eastern European IVD Markets. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan has expanded its flagship Global Congress on Corporate Growth -- GIL Global -- into several major cities around the world including London. For the first time ever in Europe, Frost & Sullivan will be hosting the Growth, Innovation and Leadership Congress 'GIL 2009: Europe' on 19-20 May, at the Sofitel St James in London. GIL Global is the industry's only event designed to support senior executives in their efforts to achieve sustainable, top-line growth. To register, obtain a programme agenda, explore sponsorship opportunities, or attend as a member of the media for GIL 2009: Europe, please contact Katja Feick, Corporate Communications Europe, at katja.feick@frost.com. One-on-One interviews with Frost & Sullivan senior growth consultants are also being scheduled. For more information you can also visit http://www.frost.com/gilglobal

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

                      European Cancer IVD Market (M2EC)

     Contact:
     Katja Feick
     Corporate Communications - Europe
     P: +49 (0) 69 7703343
     E: katja.feick@frost.com
    http://www.frost.com

'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Supernanny Jo Frost Joins the Partnership for a Drug-Free America in Supporting Time To Talk(TM)
2. Masimo Corporation Receives a Frost & Sullivan 2007 Industry Best Practices Award for Pulse Oximetry Leadership
3. Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award
4. Novadaqs SPY Imaging System named Product of the Year by Frost and Sullivan
5. Gary Tschautscher of Nonin Medical, Inc. Receives CEO of 2007 for North American Patient Monitoring From Frost & Sullivan
6. Kelloggs Frosted Flakes Gold(TM) Helps Moms Get the Gold
7. MedApps Receives Prestigious Frost & Sullivan Award
8. Nancy Frost Joins Lawson-Hawks as Employee Benefits Vice President
9. Accurays CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan
10. Help Your Kids Earn an A for Attentiveness with a Bowl of Frosted Mini- Wheats(R) Cereal for Breakfast
11. Therapy Could Save Limbs After Frostbite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... (PRWEB) February ... for the nation to come together to combine its favorite ... with its favorite fruit – apples! To celebrate National Nutrition ... join the “Apple Madness” bracket tournament – a five-week, five-round ...
(Date:2/23/2017)... ... 23, 2017 , ... Thomas Vas-Don suffered from severe injury due ... was able to successfully recover. In “ Origin & Insertion Charts for Massage Therapists ... the principals of massage, anatomy , trigger points and referral pain patterns ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... in recent years. The technology is so cutting edge, in fact, the U.S. ... for stem cell procedures. However, successful patient outcomes in certain clinical stem cell ...
(Date:2/22/2017)... ... February 22, 2017 , ... Giving patients with diabetes ... emergency room, fewer hospital admissions, and better blood pressure and glycemic control, a ... The study can be found here . , The study comes as ...
(Date:2/22/2017)... ... February 22, 2017 , ... Sideline Products participated in the World Horse ... host Tom Seay and his production crew. Tom Seay’s program “Best of America ... world. Saddle Sidekicks will be featured on April 6, 2017. After the broadcast, ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 23, 2017 LG Innotek today announced that the company ... As its sterilization performance is 1.5 times higher than the competitor,s ... rays in the range of 200 -- 280nm, allowing it to be ... destroying their DNA. LG Innotek,s product emits UV in the range ... Until ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... to 2025" report to their offering. ... The Global Cardiac Prosthetic Devices Market ... the next decade to reach approximately $8.9 billion by 2025. ... all the given segments on global as well as regional levels ...
(Date:2/23/2017)... 23, 2017 Tillotts Pharma is ... Berlin office was opened in January ... The portfolio includes Entocort ® for the treatment ... of ulcerative colitis, and VistaPrep ® for bowel ... specialty pharmaceutical company focused on the treatment of gastrointestinal ...
Breaking Medicine Technology: